Seres Therapeutics (MCRB)

The company’s pipeline includes candidates such as SER-155 and SER-603. These programmes are designed to address conditions involving bacterial infections, antimicrobial resistance and gastrointestinal immune disorders. SER-155 is intended to reduce the risk of infections and other complications in medically vulnerable patients, while SER-603 reflects the company’s broader effort to develop next-generation microbiome therapies. Seres operates as a single reportable segment centred on the research and development of microbiome-based treatments.

Seres is known as one of the early public biotechnology companies dedicated to live biotherapeutics. Its scientific approach involves selecting bacterial strains or microbial consortia with defined therapeutic aims, rather than using the microbiome only as a diagnostic or research tool. That focus gives the company a differentiated role in the biotech market, but it also exposes it to the development risks typical of clinical-stage drug companies, including trial outcomes, regulatory review, manufacturing complexity and funding needs.

MCRB is the company’s common stock. Investors generally evaluate Seres by monitoring clinical progress, partnership activity, cash resources and the potential commercial relevance of its microbiome platform.